» Articles » PMID: 37563148

Potential Factors for and the Prognostic Impact of Ascites After Allogeneic Hematopoietic Stem Cell Transplantation

Overview
Journal Sci Rep
Specialty Science
Date 2023 Aug 10
PMID 37563148
Authors
Affiliations
Soon will be listed here.
Abstract

Ascites is sometimes detected after allogeneic hematopoietic stem cell transplantation (allo-HSCT); however, since limited information is currently available, its clinical meaning remains unclear. Therefore, we herein examined potential factors for and the impact of ascites on the prognosis of patients after allo-HSCT at our institutes. Fifty-eight patients developed ascites within 90 days of allo-HSCT (small in 34 (16%), moderate-large in 24 (11%)). A multivariate analysis identified veno-occlusive disease/sinusoidal obstruction syndrome (p = 0.01) and myeloablative conditioning (p = 0.01) as significant potential factors for the development of small ascites. Thrombotic microangiopathy (TMA) (p < 0.01) was a significant potential factor for moderate-large ascites. The incidence of both small and moderate-large ascites correlated with lower overall survival (p = 0.03 for small ascites and p < 0.01 for moderate-large ascites) and higher non-relapse mortality rates (p = 0.03 for small ascites and p < 0.01 for moderate-large ascites). Lower OS and higher NRM rates correlated with the incidence of both small and moderate-large ascites. Further investigation is warranted to establish whether the clinical sign of ascites improves the diagnostic quality of TMA in a large-scale study.

Citing Articles

Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation.

Masuda Y, Honda A, Oyama T, Masamoto Y, Kurokawa M Int J Hematol. 2025; .

PMID: 40032737 DOI: 10.1007/s12185-025-03949-7.


Pretransplant Minimal Pleural and Peritoneal Effusion Is a Potential Poor Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation.

Oyama T, Honda A, Masuda Y, Morita K, Maki H, Masamoto Y Clin Transplant. 2025; 39(1):e70072.

PMID: 39761366 PMC: 11703418. DOI: 10.1111/ctr.70072.


Case report: Nephrotic syndrome and portal hypertensive ascites after allogeneic hematopoietic stem cell transplantation: a rare manifestation of chronic graft-versus-host disease.

Ai S, Wen Y, Fan X, Hua T, Ye W, Li X Front Immunol. 2024; 15:1464616.

PMID: 39478870 PMC: 11521799. DOI: 10.3389/fimmu.2024.1464616.

References
1.
Varma A, Abraham S, Mehta R, Saini N, Honhar M, Rashid M . Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020; 4(7):1296-1306. PMC: 7160275. DOI: 10.1182/bloodadvances.2019000638. View

2.
McDonald G, Slattery J, Bouvier M, Ren S, Batchelder A, Kalhorn T . Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2002; 101(5):2043-8. DOI: 10.1182/blood-2002-06-1860. View

3.
Seber A, Khan S, Kersey J . Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Bone Marrow Transplant. 1996; 17(2):207-11. View

4.
Ho V, Cutler C, Carter S, Martin P, Adams R, Horowitz M . Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11(8):571-5. DOI: 10.1016/j.bbmt.2005.06.001. View

5.
ANDERSON J, Cain K, Gelber R . Analysis of survival by tumor response. J Clin Oncol. 1983; 1(11):710-9. DOI: 10.1200/JCO.1983.1.11.710. View